If You Invested in Compass Therapeutics, Inc. (CMPX)
Looking for the current price? See the CMPX quote & overviewWhat $1,000 or $10,000 in CMPX Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Apr 6, 2021 |
|---|---|---|---|---|
| $1,000 | $125 -88% | $176 -82% | — | $72 -93% |
| $10,000 | $1,247 -88% | $1,756 -82% | — | $719 -93% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-18. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for CMPX$1,000 Investment Over Time
CMPX vs S&P 500Year-by-Year Returns
CMPX annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021Apr 6 to Dec 31 | $8.50 | $3.17 | -62.7% | -62.7% |
| 2022 | $3.17 | $5.03 | +58.7% | -40.8% |
| 2023 | $5.03 | $1.56 | -69.0% | -81.6% |
| 2024 | $1.56 | $1.45 | -7.1% | -82.9% |
| 2025 | $1.45 | $5.37 | +270.3% | -36.8% |
| 2026Dec 31, 2025 to Nov 18 | $5.37 | $0.6110 | -88.6% | -92.8% |
About Compass Therapeutics, Inc.
Healthcare · NASDAQ
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth, with the goal of generating effective anti-tumor responses across a range of solid and hematologic malignancies. Compass Therapeutics was founded in 2014 and is headquartered in Boston, Massachusetts.
According to the company’s public disclosures, Compass has built a pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These pathways include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.
Core scientific focus and therapeutic approach
Compass Therapeutics describes its scientific strategy as centered on the interplay between angiogenesis (the formation of new blood vessels), immune regulation, and tumor biology. By targeting angiogenesis, the company aims to affect the tumor microvasculature, which can influence how tumors grow and respond to therapy. At the same time, its programs seek to activate effector cells in the tumor microenvironment and reduce immunosuppressive mechanisms that allow tumors to evade immune surveillance.
This multi-pathway approach is reflected in the company’s antibody-based product candidates, many of which are bispecific antibodies designed to engage more than one target. Publicly described programs include antibodies directed at DLL4 and VEGF-A, PD-1 and PD-L1, PD-1 and VEGF-A, and CD137. These targets are associated with angiogenesis, immune checkpoint regulation, and immune cell co-stimulation, which together are intended to support a coordinated anti-tumor immune response.
Key clinical and preclinical product candidates
Compass Therapeutics reports a pipeline that includes several named product candidates:
- Tovecimig (DLL4 x VEGF-A bispecific antibody) – A bispecific antibody that targets DLL4 and VEGF-A. Tovecimig is being evaluated in the Phase 2/3 randomized COMPANION-002 study in patients with advanced biliary tract cancer (BTC). The company has stated that this study met its primary endpoint of overall response rate when tovecimig plus paclitaxel was compared with paclitaxel alone, and that analyses of key secondary endpoints, including progression-free survival (PFS) and overall survival (OS), are planned based on pre-specified events. Tovecimig has also been studied as monotherapy in patients with advanced, metastatic colorectal cancer (CRC) treated in later-line settings, where Compass has reported monotherapy activity and has highlighted outcomes in patients with DLL4-positive tumors.
- CTX-8371 (PD-1 x PD-L1 bispecific antibody) – A bispecific antibody targeting PD-1 and PD-L1. In a Phase 1 dose-escalation study, Compass has reported responses in patients with both solid tumors and hematologic malignancies in the post-checkpoint inhibitor setting. Public updates describe deep and durable responses in indications such as non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC), as well as responses in Hodgkin Lymphoma (HL). The company has opened cohort expansions for CTX-8371 in TNBC and NSCLC and is evaluating potential accelerated pathways for HL in the post-checkpoint inhibitor setting.
- CTX-10726 (PD-1 x VEGF-A bispecific antibody) – A bispecific, tetravalent antibody that simultaneously targets VEGF-A and PD-1. Compass reports that CTX-10726 is being developed for metastatic or locally advanced tumor types where checkpoint and angiogenesis signals are present. In preclinical studies described by the company, CTX-10726 demonstrated high-affinity binding to VEGF-A and PD-1, blocked VEGF-A/VEGFR2 and PD-1/PD-L1 interactions in a dose-dependent manner, and showed anti-tumor activity in multiple in vivo models. The company has indicated that CTX-10726 is undergoing IND-enabling studies and that it plans a Phase 1 dose-escalation study.
- CTX-471 (CD137 agonist antibody) – A CD137 (4-1BB) agonist antibody that Compass states binds a unique epitope of the co-stimulatory molecule 4-1BB with an optimized affinity. The company has indicated that it expects to initiate a Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56).
In addition to these named programs, earlier descriptions of the company’s pipeline reference candidates such as CTX-009 and a VEGF-IO bispecific, reflecting a broader effort to explore multiple antibody formats and targets within its core scientific framework.
Oncology focus and disease areas
Compass Therapeutics characterizes itself as an oncology-focused biopharmaceutical company. Across its clinical and preclinical programs, the company’s disclosures reference work in advanced biliary tract cancer, colorectal cancer, non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma, among other DLL4-positive and PD-(L)1-positive tumor types. The company’s public statements emphasize development in settings where patients often have limited approved therapeutic options, including later-line treatment of certain cancers and post-checkpoint inhibitor settings.
By designing antibodies that engage angiogenesis pathways and immune checkpoints simultaneously, or that provide immune co-stimulation, Compass aims to address tumors that may not respond adequately to single-pathway therapies. The company’s pipeline is described as being suitable for evaluation both as monotherapy and in combination with other agents, including standard-of-care regimens and other proprietary antibodies.
Capital markets and listing information
Compass Therapeutics, Inc. is listed on the Nasdaq Capital Market under the trading symbol CMPX. The company has filed shelf registration statements and conducted underwritten public offerings of common stock and pre-funded warrants, as described in its Form 8-K filings. In these filings, Compass has stated that it intends to use offering proceeds to fund research and clinical development of its product candidates, initial preparations for commercial readiness, and general corporate purposes. The company has also disclosed expectations regarding its cash and marketable securities and anticipated cash runway, while noting that these expectations are based on assumptions that may change.
Regulatory and reporting profile
As a U.S. public company, Compass Therapeutics files periodic and current reports with the Securities and Exchange Commission (SEC), including Forms 10-K, 10-Q, and 8-K. Recent 8-K filings have covered financial results, corporate presentations, and material financing agreements. These filings provide additional detail on the company’s operating expenses, research and development activities, general and administrative costs, and balance sheet items such as cash, marketable securities, and lease obligations.
Position within biopharmaceutical development
Within the broader biopharmaceutical landscape, Compass Therapeutics presents itself as a company focused on antibody engineering and immuno-oncology. Its emphasis on bispecific antibodies targeting combinations such as DLL4/VEGF-A, PD-1/PD-L1, and PD-1/VEGF-A, alongside a CD137 agonist program, reflects a strategy of engaging multiple mechanisms relevant to tumor growth, angiogenesis, and immune modulation. Publicly available information highlights the company’s intention to use clinical and nonclinical data to guide the advancement of these candidates, including decisions about monotherapy versus combination approaches and selection of tumor types for further study.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Compass Therapeutics, Inc. investment returns
How much would $1,000 invested in Compass Therapeutics, Inc. be worth today?
If you invested $1,000 in Compass Therapeutics, Inc. (CMPX) 5 years ago on 2021-11-19, your investment would be worth $176 as of 2026-11-18, a -82.4% price return without dividends, growing at a compounded rate of -29.4% per year (CAGR).
Has Compass Therapeutics, Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare CMPX performance over available time periods.
What is Compass Therapeutics, Inc.'s average annual return?
The compound annual growth rate (CAGR) of CMPX’s share price over the past 5 years is -29.4%, without dividends. Individual years vary a great deal, and CMPX’s best recent full year was 2025 (+270.3%) while the worst was 2023 (-69.0%).
For informational and educational purposes only, not investment advice.